• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Response to the letter to editor: Prediction of thromboembolic events for patients with non-valvular atrial fibrillation; CHA2DS2-VASc-UA2-VitD
We are invited to comment on the letter written by Dr. Cerit in reference to our recently article[1]. In the letter, Dr. Cerit concluded that vitamin D (VD) was closely related to atrial fibrillation and ischemic stroke, and hypothesized that CHA2DS2-VASc-UA2-VitD may be an useful score system in risk stratification of patients with non-valvular atrial fibrillation (NVAF). Several reasons were given in the letter: 1) VD regulates oxidative stress [2]. 2) VD may prevent and terminate atrial fibrillation as the direct electromechanically of left atrium [3].
Source: International Journal of Cardiology - December 5, 2016 Category: Cardiology Authors: Jun Guo Tags: Correspondence Source Type: research

Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials
The efficacy and safety of warfarin for stroke prevention in atrial fibrillation (AF) depend on the time in the therapeutic range (TTR) with an international normalised ratio (INR) of 2.0 –3.0. This meta-analysis focused the relative efficacy and safety of non-VKA oral anticoagulants (NOAC) compared with warfarin at different thresholds of centre's TTR (cTTR).
Source: International Journal of Cardiology - June 2, 2017 Category: Cardiology Authors: Jo ão Carmo, Jorge Ferreira, Francisco Costa, Pedro Carmo, Diogo Cavaco, Salomé Carvalho, Francisco Morgado, Pedro Adragão, Miguel Mendes Source Type: research

Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?
We read the article “Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation” by Fernando Dominguez et al. [1] interestingly, which has great clinical significance in guiding the use of oral anticoagulants in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrilla tion (AF). Due to the high risk of stroke and thromboembolic complications in patients with HCM and AF, vitamin K antagonists (VKAs) are recommended for those patients, direct oral anticoagulants (NOACs) may represent another option [2].
Source: International Journal of Cardiology - February 15, 2018 Category: Cardiology Authors: Biao Li, Chao Sun, Fen Qin, Na Liu, Zhihong Wu, Qiming Liu Tags: Letter to the Editor Source Type: research

Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a fixed dosing regimen. Despite the potential for relative underdosing due to large distribution volumes, dose adjustments for patients with high body mass index (BMI) are not recommended. Since efficacy and safety data in obese patients are scarce, we evaluated the impact of BMI on clinical outcomes in daily care patients treated with NOAC for stroke prevention in atrial fibrillation or venous thromboembolism.
Source: International Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: L. Tittl, S. Endig, S. Marten, A. Reitter, I. Beyer-Westendorf, J. Beyer-Westendorf Source Type: research

The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence increases with age. Age also increases the risk of thromboembolism related to AF. As a result, elderly patients are at increased risk of AF-related stroke compared to younger patients. Age, however, also increases the risk of bleeding, including that of intracranial haemorrhage, an important cause of death and disability. Elderly patients with AF are, therefore, often undertreated due to the fear of bleeding complications, although recent data suggest an even greater net clinical benefit for anticoagulation in general in the elderly, even the very el...
Source: International Journal of Cardiology - June 7, 2018 Category: Cardiology Authors: Giuseppe Patti, Ilaria Cavallari, Olivier Hanon, Raffaele De Caterina Source Type: research

The great discovery of DOACs and why physicians insist on misusing it: A paradox of the 21 century
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and has been one of the most studied disease in the world for the last 20  years. As it is a frequent cause of preventable strokes, substantial research efforts were directed toward gaining detailed information about effective prophylactic treatments. New evidence has been continuously published and resulted in the approval of direct-acting oral anticoagulants (DOACs) i n this scenario, which are safer and easier to use than vitamin K antagonists (VKA).[1]Although the randomized clinical trials that substantiated the approval of DOACs were based in ...
Source: International Journal of Cardiology - June 1, 2022 Category: Cardiology Authors: Fl ávia Bittar B. Arantes, Remo H.M. Furtado Tags: Editorial Source Type: research

Pages: 1  2  3  4